Raj Chovatiya, MD, PhD

Articles by Raj Chovatiya, MD, PhD

Emerging Treatment Options in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 15th 2023

Expert dermatologists consider ongoing trials and emerging treatment options for the management of AD.

Guidance for Topical Treatment Use Based on BSA in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 15th 2023

Experts in dermatology share general guidance for use of topicals, switching from topical to systemic treatment, and when combination therapy is an option for patients with atopic dermatitis.

Challenges and Advantages in Use and Access to Biologics for Atopic Dermatitis

ByRaj Chovatiya, MD, PhD,George Han, MD, PhD,Vivian Shi, MD, FAAD

March 13th 2023

Drs Raj Chovatiya, George Han, and Vivian Shi review the current challenges and opportunities surrounding the utilization and availability of biologic therapies in atopic dermatitis.

Considerations for Biologic Treatments in Pediatric Patients with Atopic Dermatitis

ByRaj Chovatiya, MD, PhD,George Han, MD, PhD,Vivian Shi, MD, FAAD

March 13th 2023

Expert dermatologists highlight the burden of atopic dermatitis in young children and examine the clinical data for dupilumab, a biologic treatment for this age group.

Therapy Individualization for Atopic Dermatitis

ByRaj Chovatiya, MD, PhD,George Han, MD, PhD,Vivian Shi, MD, FAAD

March 13th 2023

The expert panel discusses the heterogeneity of atopic dermatitis manifestation and therapy decisions for individual patients.

Treatment Landscape in Atopic Dermatitis for Different Age Groups

ByRaj Chovatiya, MD, PhD,George Han, MD, PhD,Vivian Shi, MD, FAAD

March 13th 2023

Dr Vivian Shi provides an overview of treatment options for atopic dermatitis patients in different age groups.

Monitoring AD Treatments in Various Age Groups

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 8th 2023

Omar Noor, MD, and Adelaide A. Hebert, MD, discuss monitoring requirements for various classes of treatments in atopic dermatitis, including topical vs systemic.

Treatment Options for Patients With Moderate Disease Over 10%-20% BSA

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 8th 2023

Peter A. Lio, MD, reviews treatment options for patients with moderate AD.

Treatment Goals in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 1st 2023

Matthew Zirwas, MD, shares goals of therapy for a patient with AD.

Implications of Boxed Warnings of Topical JAK inhibitors

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 1st 2023

Expert dermatologists address the clinical implications of boxed warnings of topical treatments in AD.

Time to Response in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 22nd 2023

Matthew Zirwas, MD, and Omar Noor, MD, comment on their own experience of time to response with topical and systemic treatments of AD.

Durability of Response to Treatment in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 22nd 2023

Peter A. Lio, MD, discusses the durability of topical treatments in AD, including steroids, calcineurin inhibitors, and JAK inhibitors.

Efficacy Data for Topical Treatment of AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 15th 2023

Experts discuss long-term efficacy data for topical medications for the treatment of AD.

Patient With Limited Disease Activity in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 15th 2023

Matthew Zirwas, MD, and Omar Noor, MD, review a patient scenario where AD disease activity is limited but in difficult to treat locations.

AD Treatment Options for Patients Moving Away from Long-Term Steroids

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 8th 2023

Peter A. Lio, MD, shares his approach to presenting treatment alternatives to patients who want to stop using long-term steroids for treatment of AD.

Challenges Faced by Non-Dermatologists When Using Steroids

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 8th 2023

Adelaide A. Hebert, MD, comments on the need for nondermatologist education on the basics of skin disease care.

Durability of Topical Steroid Use in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 1st 2023

Expert dermatologists discuss the durability of long-term use of topical steroids for treatment of atopic dermatitis.

Patient on Long-Term Steroidal Use in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 1st 2023

Adelaide A. Hebert, MD, reviews the use of long-term steroids for treatment of atopic dermatitis.

Advice for Managing Patients With PN

ByRaj Chovatiya, MD, PhD,Shawn Kwatra, MD,Sarina B Elmariah, MD, PhD

January 27th 2023

Shawn Kwatra, MD, and Sarina B. Elmariah, MD, PhD, share final pearls of wisdom for other physicians taking care of patients with prurigo nodularis (PN).

Unmet Needs in PN

ByRaj Chovatiya, MD, PhD,Shawn Kwatra, MD,Sarina B Elmariah, MD, PhD

January 27th 2023

Experts in dermatology discuss unmet needs in prurigo nodularis (PN) and the importance of addressing those needs for disease management.

Emerging Treatments for PN

ByRaj Chovatiya, MD, PhD,Shawn Kwatra, MD,Sarina B Elmariah, MD, PhD

January 27th 2023

Drs Raj Chovatiya, Shawn Kwatra, and Sarina B. Elmariah review exciting new therapies in the treatment landscape of PN.

Factors Guiding Treatment Selection in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

January 26th 2023

Experts in dermatology discuss which disease characteristics play the biggest role in influencing treatment choice or change of treatment from the perspective of a patient with atopic dermatitis.

Treatment Options and Targets in Atopic Dermatitis (AD)

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

January 25th 2023

A panel of expert dermatologists comments on newly approved and traditional treatment options, addressing how they target inflammation and the pathophysiology of atopic dermatitis (AD).

Conducting Additional Research to Improve PN Management

ByRaj Chovatiya, MD, PhD,Shawn Kwatra, MD,Sarina B Elmariah, MD, PhD

January 20th 2023

Experts in dermatology share thoughts on the need for additional investigative research of prurigo nodularis in order to better treat patients.

Challenges in Using Dupilumab in PN

ByRaj Chovatiya, MD, PhD,Shawn Kwatra, MD,Sarina B Elmariah, MD, PhD

January 20th 2023

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss potential challenges to the adoption of dupilumab in the treatment of PN.